ROCHESTER, Minn. — Chemotherapy is usually the first treatment doctors try to treat lymphoma, including the two most common forms: non-Hodgkin and Hodgkin. But alternatives to chemotherapy are ...

Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...

Given the multiple treatment options with high efficacy for disease control, we also present considerations of cumulative doses of therapy, subtle issues regarding trial eligibility and subgroup ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Stage 4 lymphoma is a cancer of white blood cells called lymphocytes that has spread outside the lymph nodes to other parts of the body. While this is an advanced stage, treatment options are ...

Anaplastic Large-Cell Lymphoma: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty Anaplastic Large-Cell Lymphoma (ALCL) is a rare and aggressive type of non-Hodgkin lymphoma that ...

Various treatments are available for lymphoma, including chemotherapy, radiation, immunotherapy, targeted therapy, or a bone marrow transplant. A doctor or specialist can recommend which treatment is ...

Radiation therapy (also called radiotherapy) uses high-energy beams or atoms to damage the DNA inside cancer cells. After enough damage, the cells cannot multiply, and they die. Based on your subtype ...

Christina Poh, MD, of City of Hope National Medical Center, highlights the benefit of tafasitamab in improving progression-free survival for heavily pretreated patients with relapsed or refractory ...

NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in ...

Please provide your email address to receive an email when new articles are posted on . The results were presented at Society of Hematologic Oncology’s Annual Meeting. “We currently are really missing ...